Compound modulators of sting

A compound of formula I:

• wherein:
• Y is either (CH2)n, where n is from 2 to 4, or —CH2—CH═CH—CH2—;
• R1 and R11 are independently selected from —C(═O) OH, —C(═O) ORP1, Br, F, tetrazolyl, oxo-oxadiazolyl and
• (2H-triazol-4-yl), where RP1 is selected from methyl and ethyl;
• A1 is CRA or N;
• A2 is CRB or N;
• A3 is CRC or N;
• A4 is CRD or N;
• where no more than two of A1, A2, A3, and A4 may be N;
• one, two or three of RA, RB, RC and RD, (if present) are selected from H, F, Cl, Br, I, Me, Et, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH;
• the remainder of RA, RB, RC and RD, (if present) are H;
• A11 is CRAA or N;
• A12 is CRBB or N;
• A13 is CRCC or N;
• A14 is CRDD or N;
• where no more than two of A11, A12, A13 and A14 may be N;
• one, two or three of RAA, RBB, RCC and RDD (if present) are selected from H, F, Cl, Br, I, Me, Et, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH;
• the remainder of RAA, RBB, RCC and RDD, (if present) are H;
• RC1, RC3 and RC4 are independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl;
• RC11, RC13 and RC14 are independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4alkenyl and C5heterocyclyl;
• or a pharmaceutically acceptable salt, solvate, prodrug, geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric isomer, tautomer, polymorph or N-oxide or a combination thereof.